Diabetes drug shows promise in preventing deadly transplant reaction
NCT ID NCT05149365
First seen Feb 28, 2026 · Last updated Apr 30, 2026 · Updated 5 times
Summary
This study tested whether sitagliptin, a common diabetes medicine, could prevent acute graft-versus-host disease (GVHD) in 190 adults receiving stem cell transplants from related or unrelated donors. GVHD is a serious condition where donor cells attack the patient's body. The goal was to see if adding sitagliptin to standard care lowered the chance of developing moderate-to-severe GVHD within 100 days after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE-GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
Suzhou, Jiangsu, 215000, China
Conditions
Explore the condition pages connected to this study.